Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFFITOPE PD01A
- Development stage
- Phase 2
- Lead developer
- AC Immune
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
**AFFITOPE PD01A** is an investigational active immunotherapy vaccine developed by AFFiRiS for synucleinopathies, principally Parkinson's disease and multiple system atrophy. It comprises a synthetic eight-amino-acid peptide that mimics a C-terminal epitope of human alpha-synuclein, conjugated to keyhole limpet hemocyanin and adsorbed to aluminum hydroxide. The vaccine is intended to elicit antibodies preferentially recognizing pathological aggregated alpha-synuclein, thereby limiting aggregate propagation and supporting clearance while avoiding alpha-synuclein-directed autoreactive T-cell activation. AFFITOPE PD01A completed Phase 1 and booster studies in Parkinson's disease and Phase 1 evaluation in multiple system atrophy. It is the predecessor of AC Immune's optimized but distinct ACI-7104.056 formulation, which is being evaluated separately in Phase 2 Parkinson's disease studies. ([michaeljfox.org](https://www.michaeljfox.org/grant/phase-ib-follow-study-assess-boost-immunization-affitoper-pd01a))
- Brand names
- AFFITOPE PD01A
- Other names
- Parkinson's disease vaccine
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on AFFITOPE PD01A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFFITOPE PD01A.